LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Search

CareDx Inc

Cerrado

SectorSanidad

20.56 2.29

Resumen

Variación precio

24h

Actual

Mínimo

19.81

Máximo

20.93

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.773

84.243

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-10.85% downside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

288M

1.1B

Apertura anterior

18.27

Cierre anterior

20.56

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 feb 2026, 23:26 UTC

Principales Movimientos del Mercado

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb 2026, 22:31 UTC

Ganancias

Correction to America Movil 4Q Profit Article

10 feb 2026, 22:22 UTC

Ganancias

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb 2026, 23:51 UTC

Charlas de Mercado
Ganancias

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb 2026, 23:42 UTC

Charlas de Mercado

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb 2026, 23:40 UTC

Charlas de Mercado
Ganancias

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb 2026, 23:21 UTC

Charlas de Mercado

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb 2026, 23:21 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 feb 2026, 22:17 UTC

Charlas de Mercado

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb 2026, 22:15 UTC

Ganancias

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb 2026, 22:10 UTC

Ganancias

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb 2026, 22:10 UTC

Ganancias

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb 2026, 22:09 UTC

Ganancias

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb 2026, 22:09 UTC

Ganancias

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb 2026, 22:01 UTC

Ganancias

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb 2026, 21:54 UTC

Ganancias

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb 2026, 21:53 UTC

Ganancias

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb 2026, 21:51 UTC

Ganancias

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb 2026, 21:51 UTC

Ganancias

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:51 UTC

Ganancias

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb 2026, 21:51 UTC

Ganancias

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb 2026, 21:51 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb 2026, 21:50 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb 2026, 21:50 UTC

Ganancias

James Hardie Industries 3Q EPS 12c >JHX

10 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 feb 2026, 21:50 UTC

Ganancias

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb 2026, 21:49 UTC

Ganancias

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb 2026, 21:49 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb 2026, 21:48 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb 2026, 21:47 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

-10.85% descenso

Estimación a 12 Meses

Media 18 USD  -10.85%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

0

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

149 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat